Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab long-term extension in neovascular AMD
NCT04777201Phase 3Completed
- Sponsor
- Roche
- Start
- Apr 2021
- Primary completion
- Sep 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 27
01
Overview
A Phase 3 trial of faricimab in neovascular age-related macular degeneration (NVAMD), sponsored by Roche. Started Apr 2021; status: completed.
02
Drugs
faricimab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04777201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04777201.